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A B S T R A C T
Purpose
To evaluate long-term survival in a prospective series of patients newly diagnosed with glioblas-
toma and treated with a combination of lomustine (CCNU), temozolomide (TMZ), and radiotherapy.
Patients and Methods
Thirty-nine patients received radiotherapy of the tumor site only (60 Gy) and CCNU/TMZ
chemotherapy (n 31 received standard-dose CCNU, 100 mg/m2 on day 1 and TMZ 100 mg/m2/d
on days 2 to 6; n  8 received intensified-dose CCNU 110 mg/m2 on day 1 and TMZ 150 mg/m2
on days 2 to 6) for up to six courses.
Results
In the whole cohort, the median overall survival (mOS) was 23.1 months; 47.4% survived for 2
years, and 18.5% survived for 4 years. After a median follow-up of 41.5 months, mOS had not
been reached in the intensified group and was significantly higher than in the standard group (22.6
months; P  .024). In the intensified group, four of eight patients survived for at least 56 months,
two of them without recurrence. O6-methylguanine–DNA methyltransferase (MGMT) gene
promotor methylation in the tumor tissue was associated with significantly longer mOS (methyl-
ated, 34.3 months v nonmethylated, 12.5 months). A multivariate Cox proportional hazard model
revealed MGMT status (methylated v nonmethylated; relative risk [RR] of death, 0.43; P  .003)
and chemotherapy dose (intensified v standard; RR, 0.37; P  .012) as independent prognostic
factors. WHO grade 4 hematoxicity was observed more frequently in the intensified group
(57% v 16%).
Conclusion
The combination of radiotherapy, CCNU, and TMZ yielded promising long-term survival data in
patients with newly diagnosed glioblastoma. Intensification of CCNU/TMZ chemotherapy may add
an additional survival benefit, albeit with greater acute toxicity.
J Clin Oncol 27:1257-1261. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Despite recent improvements in surgery and com-
bined chemoradiotherapy, glioblastoma remains a
devastating disease. Standard chemoradiotherapy
includes concomitant and adjuvant temozolo-
mide (TMZ) chemotherapy and leads to a median
progression-free survival (mPFS) of 6.9months and
a median overall survival (mOS) of 14.6 months.1
When we used a combination of TMZ and lomus-
tine (CCNU) in the UKT-03 trial, we previously
reported promising survival data of an mPFS of 9
months and a high mOS of 22.6 months.2 Thirteen
of 31 patients in the UKT-03 trial were alive at the
end of the 24 months of follow-up period reported
in the previous publication.2 In this analysis, which
wascarriedout55monthsafter theaccrualof the last
patient to the UKT-03 trial, we report mature data
on long-term survival in the UKT-03 cohort. In
addition, we added the previously unpublished data
set of a pilot group of eight patients treated with an
intensifiedCCNU/TMZregimen,whichmight con-
fer even higher rates of long-term survival. Overall,
we report on the long-term survival of 39 prospec-
tively documented patients who received radiother-
apy and combined CCNU/TMZ chemotherapy as
first-line therapy for glioblastoma.
PATIENTS AND METHODS
This prospective series of patients treatedwithCCNUand
TMZincluded31patients treated in theUKT-03 trial2 and
eight patients treated in a prospective pilot group with
increased CCNU and TMZ doses. All patients received
treatment at the University of Tuebingen (Department of
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Neurology, Tuebingen, Germany) and Mainz (Departments of Neurology
and Neurosurgery, Mainz, Germany) Medical Centers. The main inclusion
criteria for both groups were histologic diagnosis of glioblastoma; surgery no
longer than 21 days before enrollment; no prior radiotherapy or chemothera-
py; age older than 18 years; Karnofsky performance score (KPS) of 70 or
higher; and no alterations in bone marrow reserve, liver function, or renal
function. Both treatment regimenswere approved by the local ethics commit-
tees. All patients gave written informed consent. In all patients, the therapy-
independentprognostic factors ofKPSat entry into the study and the extent of
resection as determined by the neurosurgeon were defined. In addition, the
study population was assigned to one of the prognostic groups developed by
recursive partitioning analysis3 and validated in a large number of glioma
patients enrolled on Radiation Therapy Oncology Group trials.4
The chemotherapy schedule included oral CCNU 100 mg/m2 on day 1
followed by TMZ 100mg/m2/d on days 2 through 6 of 6-week courses (stan-
dard group). The patients of the pilot cohort received a dose intensification of
CCNU110mg/m2onday1 followedbyTMZ150mg/m2/dondays 2 through
6 (intensified group). A maximum of six courses were delivered, individual
dose adjustmentsweremade in subsequent courses, anddiscontinuation rules
were as previously described.2 Radiotherapy was delivered during courses 1
and 2 as involved-field radiotherapy, with a total dose of 60 Gy in single daily
fractions of 2 Gy. Toxicity of the CCNU/TMZ treatment regimen was con-
tinously monitored throughout the treatment and follow-up phases in the
whole cohort. O6-methylguanine–DNA methyltransferase (MGMT) pro-
motermethylation statuswas analyzed inall available samplesbymethylation-
specific polymerase chain reaction (PCR), as previously described.2,5
Response assessment was based on contrast-enhanced magnetic reso-
nance imaging (MRI) after courses 2, 4, and 6.6 After chemotherapy, patients
were observed at 3-month intervals by clinical examination and contrast-
enhancedMRI. All patients were assessed for PFS onCCNU/TMZ and subse-
quent therapies,OS, and late toxicity.PFSandOSwere calculated fromtheday
of surgery that led to thehistologicdiagnosis of glioblastoma. SecondPFS rates
were calculated from the day of diagnosis of recurrence onMRI.
Survival data were analyzed according to the Kaplan-Meier method by
using the log-rank test for comparisons between different groups. Also, the
influences of the MGMT promoter methylation status (methylated v non-
methylated), CCNU/TMZdosing (intensified v standard), extent of resection
(complete v incomplete resection or biopsy), and Radiation Therapy Oncol-
ogyGroup recursive partitioning analysis class (III v IV orV)were analyzed in
univariate regression analyses by using a Cox proportional hazards model.
Parameters with a significant influence on survival in the univariate analysis
also were analyzed in amultivariate analysis.
RESULTS
Patient Characteristics and Therapy Applied
Thirty-nine patients were accrued betweenMarch 2002 andDe-
cember 2003. Thirty-one patients were treated in the UKT-03 trial
(standard group), and eight patients were treatedwith higher doses of
CCNU and TMZ in an additional pilot group (intensified group).
Patient characteristics are listed in Table 1. The patients of the inten-
sified groupwere older than the patients in the UKT-03 trial (median
age, 59 v 51 years) but did not differ with respect to KPS.
The patients in the intensified group received a median of 3.5
courses of CCNU/TMZ (range, one to six courses), and patients in
the UKT-03 group received a median of 4.5 courses (range, one to
six courses). Twenty-seven patients (69%) received second-line
therapy (Appendix Table A1, online only) and had an mPFS of 6
months. Eleven of 27 patients had an additional tumor resection at
recurrence. Repeat irradiation was applied in seven patients
(mPFS, 4 months), and hyperthermia in one patient. Second-line
chemotherapy consisted of intensified TMZ in 10 patients (mPFS,
7.5 months) and nimustine/teniposide in eight patients (mPFS, 3
months). Third-line (n  11; mPFS, 4 months) and fourth-line
(n  3; mPFS, 2 months) therapies included repeat irradiation,
intensified TMZ, nimustine, CCNU, pegylated liposomal doxoru-
bicine, and imatinib/hydroxyurea.
Toxicity
Acute toxicity was higher in the intensified cohort than in the
standard group, and grade 4myelotoxicity occurred in four (57%) of
seven assessable patients compared with 16% in the cohort of 31
patients treatedwith standard-dose CCNU/TMZ. As in the standard-
dose group,2 one patient in the intensified cohort died as a result of
septicemia during myelosuppression. No nonhematologic acute or
delayed toxicity was observed.
There were no signs of therapy-dependent late neurotoxicity in
the patients who survived long term. In all three patients who have
survived without recurrent disease, KPS at 54 to 69.5 months after
inclusion into the trial has not decreased. Two of three patients who
had one recurrence had a decrease of KPS from 100% to 70% and
from 80% to 50%on progression, but they have remained on a stable
KPS with successful treatment of recurrence. One additional patient
has remained on a stable KPS of 100% despite recurrence. In sum-
mary, decreases inKPS in some long-term survivorswere attributable
to recurrent disease but not to CCNU/TMZ therapy.
Long-Term Survival and Dependency on MGMT
Promoter Methylation Status
In the whole cohort of 39 patients, the mPFS was 10 months
(range, 1 to 69months). ThemOSwas 23.1months (Fig 1).OSwas
47.4% at 2 years, 26.4% at 3 years, 18.5% at 4 years, and 15.8% at 5
years. Four (10.3%) of 39 patients have had no recurrence at last
Table 1. Demographic and Clinical Data of Patients Treated With CCNU
and Temozolomide
Characteristic
Patients (N  39)
No. %
Age, years
 50 11 28
 50 28 72
Sex
Male 31 79
Female 8 21
KPS
100 9 23
80-90 25 64
70 5 13
Extent of surgery
Complete resection 14 36
Partial resection 19 49
Biopsy 4 10
NA 2 5
RTOG RPA class
III 8 21
IV 24 62
V 7 18
Abbreviations: CCNU, lomustine; KPS, Karnofsky performance score; NA, not
assessable; RTOG RPA, Radiation Therapy Oncology Group recursive parti-
tioning analysis.
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follow-up. Two (25%) of eight patients in the intensified group have
remained recurrence free.
Eight of 19 investigated patients in the standard group and
three of four investigated patients of the intensified group had a
methylated MGMT promotor. Survival strongly depended on the
MGMT promoter methylation status. The mPFS (Fig 2A) was
significantly higher in the methylated group (19 months; n  11)
than in thenonmethylatedgroup(7months; n12;P .0064 for the
comparison). This also translated into a substantial OS benefit (Fig
2B) for patients with a methylated MGMT promoter: mOS was 12.5
months for nonmethylated-status patients but was 34.3 months for
methylated-status patients (P .0009). In themethylated group, 45%
of patients survived for 3 years, and 36% of patients survived for
5 years.
Influence of Dose Escalation on Survival
In the standard group, the mPFS was 9 months (range, 1.9 to
 54months; Fig 3A) and themOSwas 22.6months.2 The long-term
survival analysisnowshows41.9%ofpatients surviving2years, 16.9%
of patients surviving 3 years, and 9.7% surviving 4 years (Fig 3B). In
contrast, the eight patients in the intensified grouphad anmPFS of 26
months, andmOSwas not yet reached after amedian follow-up time
of 41.5 months (range, 1 to 69 months). Both PFS (P .014) and
OS(P .024)were significantlyhigher in the intensifiedgroupthan in
thestandardgroup.Fourofeightpatients in the intensifiedgrouphave
currently survived for at least 56 months, and two of them have
survived without any recurrence or signs of late neurotoxicity. Of the
four patients in the intensified group who could be assessed for
MGMT promoter status, the three patients with a methylated pro-
moter have all still survived after a follow-up time of 56 to 70months,
whereas the patient with a nonmethylated MGMT promoter died
after 28months.
A univariate Cox proportional hazards analysis identified
MGMT promoter methylation status and chemotherapy dose as fac-
tors thathavean influenceonsurvival (Table2). Incontrast, theextent
of resection and the Radiation Therapy Oncology Group recursive
partitioning analysis class have no such effect. A subsequentmultivar-
iate analysis confirmed that the presence of a methylated MGMT
promoter and the application of intensified CCNU/TMZ were asso-
ciated with a significantly reduced risk of death (Table 2).
DISCUSSION
The data presented here suggest that the combination of CCNU,
TMZ, and radiotherapy has encouraging activity in patients with
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Fig 1. Overall survival in the cohort of 39 patients who received lomustine/
temozolomide combined with radiotherapy as first-line therapy for glioblastoma.
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Fig 2. (A) Progression-free survival (PFS) and (B) overall survival (OS) according
to the MGMT promoter methylation status in 23 assessable patients (unmethyl-
ated, n  12; methylated, n  11). Differences in survival between the two
groups were statistically significant (log-rank test; P  .0064 for PFS and
P  .0009 for OS).
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newly diagnosed glioblastoma and may lead to a substantial rate of
patients with long-term survival.
The rate of long-term survivors of greater than 24 months is
stunning, at almost 50% in the whole cohort. To our knowledge, this
might be the best rate ever observed in a prospective glioblastoma
analysis, and it does not appear to be bias driven.2 Patients with a
nonmethylated MGMT promoter in our trial survived only 12.5
months, which is virtually identical to the median survival seen in
previous trials,7 and this suggests that the patients in our series have
not been selected for good therapy-independent prognostic factors.
The increased 2-year survival rate is biologically meaningful in that
patients who benefit from chemotherapy seem to have a potential for
long-termsurvival.Althoughhistorical comparisonsmaynotbe legit-
imate, CCNU/TMZ almost doubled the percentage of survivors at 24
months (47.5%) compared with the European Organisation for Re-
search andTreatment of Cancer/National Cancer Institute of Canada
trial that used TMZ monotherapy (26.5%).1 The comparison with
such historical data has to be taken with caution, because MGMT
promoter methylation status is not known in many of our patients
(41%) and because potential differences in the number of patients
with methylated MGMT promoter may have a significant impact on
survival data. With a survivor rate of 16% after 5 years, the rate of
patients who are surviving long term andwho are potentially cured is
also increased, comparedwith the rate of 4% to 5% that is commonly
reported for glioblastoma.8 In contrast to other studies on long-term
survivors,whichhavepatientswhosemedianages are40.2 years8 or51
years,9 the long-termsurvivors inour studyarenotparticularlyyoung:
the median age was 57 years (range, 29 to 67 years). Long-term sur-
vival was mainly induced by the efficient primary treatment that
consisted ofCCNU/TMZ. Four of sevenpatientswho survived longer
than 4 years have not relapsed at last follow-up, andmPFSwas longer
duringCCNU/TMZtherapy (mPFS, 10months) thanduring second-
line therapy (mPFS, 6months) or during additional salvage therapies.
However, the high rate of patients who received a second resection
(28%)ormultiple salvage therapies or bothmight influence theOS to
some extent.
As in the UKT-03 cohort, the MGMT promoter status re-
mains a strong factor to predict the benefit from therapy in the
whole cohort of patients treated with standard or intensified
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Fig 3. (A) Progression-free survival (PFS) and (B) overall survival (OS) according
to the chemotherapy dosing. Thirty-one patients received standard-dose chem-
otherapy (standard; lomustine [CCNU] 100 mg/m2 on day 1, temozolomide [TMZ]
100 mg/m2 on days 2 to 6), and eight patients received intensified-dose
chemotherapy (intensified; CCNU 110 mg/m2 on day 1, TMZ 150 mg/m2 on days
2 to 6). Differences in survival between the two groups were statistically
significant (log-rank test; P  .014 for PFS and P  .024 for OS).
Table 2. Univariate and Multivariate Cox Regression Analysis for Factors That
Potentially Influence Overall Survival in Patients Treated With CCNU and TMZ
Factor by Analysis Type
No. of
Patients
(N  39)
Median
Survival
(months)
Analysis
HR 95% CI P†
Univariate
RTOG RPA class‡ 1.06 0.66 to 1.57 .78
III 8 22.9
IV or V 31 24.8
Extent of resection 0.89 0.61 to 1.27 .52
Complete 14 27.5
Partial or biopsy 23 22.6
MGMT promoter status 0.40 0.20 to 0.70 .001
Methylated 11 34.3
Nonmethylated 12 12.5
CCNU/TMZ dosing 0.52 0.25 to 0.89 .013
Intensified 8  41.5
Standard 31 22.6
Multivariate
MGMT promoter status 0.43 0.22 to 0.76 .003
Methylated 34.3
Nonmethylated 12.5
CCNU/TMZ dosing 0.37 0.09 to 0.83 .012
Intensified 8  41.5
Standard 31 22.6
Abbreviations: CCNU, lomustine; TMZ, temozolomide; RTOG RPA, Radiation
Therapy Oncology Group recursive partitioning analysis; MGMT, O6-
methylguanine-DNA methyltransferase.
Comparison of condition 1 versus condition 2 for each factor.
†2 test.
‡RTOG RPA integrates data on performance score, age, and extent of resection.
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CCNU/TMZ. The median survival time of patients with a non-
methylated MGMT promoter is 12.5 months, which is essentially
the time that is achieved with radiotherapy alone as the first-line
treatment.1 InpatientswithamethylatedMGMTpromoter, themOS
(34.5months) is almost tripled that of patients with a nonmethylated
MGMTpromoter.Obviously, there is no evidence thatCCNU/TMZ-
induced MGMT depletion breaks resistance to chemotherapy in
MGMT-nonmethylated–status patients. Thus, patients with a non-
methylated MGMT promoter in their tumor may not take benefit
fromCCNU/TMZ at any dose. Consequently, future trials that com-
bine CCNU/TMZ chemotherapy or other alkylating combination
chemotherapymaybe restricted topatientswithamethylatedMGMT
promoter or should be stratified according to MGMT promoter
methylation status.
A significant dose intensification of TMZ in the CCNU/TMZ
combination therapy appears to add an additional, marked survival
benefit in the presence of high but tolerable toxicity. Admittedly, the
group of patients with intensified CCNU/TMZ is small, and conclu-
sions are, therefore, limited, particularly because the MGMT pro-
moter methylation status is not known in many of the patients.
Nevertheless,PFSandOSin thisgroupare substantially increased, and
themOS in themixed groupof patientswithMGMT-methylated and
-nonmethylated status who were treated with intensified CCNU/
TMZ appears higher than the mOS of the patients who received
standard dose andwhohad amethylatedMGMTpromotor ( 41.5 v
27.9 months). Intriguingly, four of eight patients in the intensified
group have currently survived for at least 56 months, two of them
without recurrence. It is important to note that the excellent efficacy
data in the intensified group may not be the result of a selection of
patients with favorable prognostic factors. The inclusion criteria
were identical to the inclusion criteria of a previous large, phase III
trial.1 More importantly, the median age (59.5 years) as a major
prognostic factorwas higher than in previous trials andwas close to
the average age of patients with newly diagnosed glioblastoma in
the general population.
In conclusion, the combination of CCNU and TMZ shows
promising efficacy against newly diagnosed glioblastoma. The data
presented here demonstrate an encouraging therapeutic potential but
also demonstrate the toxic limitations of the dose-intensified regimen
in this setting. Additional studies are warranted to optimize CCNU/
TMZ combination chemotherapy.
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